Matches in Nanopublications for { ?s ?p " REPATHA is indicated in adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization. It is an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, to reduce LDL-C. In adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH)" ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- assertion wasQuotedFrom " REPATHA is indicated in adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization. It is an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, to reduce LDL-C. In adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH)" provenance.